Sector News

Reuters: Mylan chairman tells investors he would consider buying Teva

May 11, 2015
Life sciences
Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd (TEVA.TA), but would consider buying that company down the road, Mylan Executive Chairman Robert Coury told investors this week.
 
The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter drugmaker Perrigo Co Plc (PRGO.N).
 
Teva made an unsolicited $40 billion bid for Mylan last month, and it was rejected. Teva said on Tuesday it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed.
 
Mylan’s Coury said in a statement in April the company has studied a possible combination with Teva for some time. Mylan concluded a deal would be “without sound industrial logic or cultural fit” and would attract antitrust scrutiny.
 
Mylan said in April it would not engage with Teva until the company was willing to offer more than $100 per share.
 
Speaking privately to investors this week, however, Coury was more willing to consider a deal with Teva after the Perrigo transaction is completed, as long as Mylan is the buyer, sources told Reuters.
 
Mylan Chief Executive Officer Heather Bresch explained to Reuters in an interview the logic behind Coury’s comments. Mylan has a better management team and integrated global supply chain, as well as a superior track record with acquisitions. That would make it more capable than Teva to lead the potential combined company, she said.
 
A deal could make sense following a Mylan-Perrigo combination and more time for Teva’s management to “clean up” the company.
 
“We were just saying in a hypothetical situation, if it ever were to happen after all these other things, the only way it could happen is with us,” Bresch said. She added antitrust concerns would still exist.
 
The investor sources declined to be named because they are not authorized to speak with the media.
 
A Teva spokesman said the company remains deeply committed to a deal with Mylan and that there is strong strategic and cultural fit in combining the two companies.
 
Mylan management is meeting privately with top investors this week in New York and Boston to drum up support for its bid for Perrigo. Perrigo last week rejected Mylan’s latest offer worth $75 and 2.3 Mylan shares per Perigo share, up from a previous $60 in cash and 2.2 shares.
 
Mylan, which makes the EpiPen product for severe allergies, is incorporated in the Netherlands and can take advantage of Dutch provisions that would make a hostile takeover difficult.
 
Pressure has been growing on Jerusalem-based Teva for new revenue sources. Its biggest selling drug, multiple sclerosis injectable treatment Copaxone, faces competition from oral treatments and cheaper generics in the coming years.
 
(Reporting by Olivia Oran and Caroline Humer in New York; Editing by Ted Botha and Andre Grenon)

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach